INDP — Indaptus Therapeutics Balance Sheet
0.000.00%
- $7.88m
- $1.72m
Annual balance sheet for Indaptus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 14.7 | 39.1 | 26.4 | 13.4 | 5.79 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.085 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 15 | 40.4 | 27.2 | 14 | 6.62 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.21 | 0.173 | 0.081 | 0.174 | 0.082 |
| Other Long Term Assets | |||||
| Total Assets | 20.9 | 40.6 | 28.1 | 14.9 | 7.34 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.33 | 4.6 | 3.43 | 2.77 | 3.39 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 6.36 | 4.68 | 3.43 | 2.85 | 3.39 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 14.5 | 35.9 | 24.6 | 12.1 | 3.94 |
| Total Liabilities & Shareholders' Equity | 20.9 | 40.6 | 28.1 | 14.9 | 7.34 |
| Total Common Shares Outstanding |